SCT-A12

N/A

Report date: 2025/06/12 17:08:49

Base Information

Drug NameSCT-A12
Drug Alias NameSCTA12SCT-A12
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsCD22 inhibitors
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSinoCelltech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A